Aug 06, 2026
P21 for GLP-1 Cognitive Fog: VA Trial Lessons
GLP-1 agonists can cause cognitive fog, but a 2023 VA trial on P21 for alcohol-related impairment offers clues. This peptide...
Read articleFIELD NOTES
Reading material for serious researchers.
Research notes, product guides, and insights from the Lakeshore Peptides team.
Aug 04, 2026
P21 and GLP-1 Alcohol Trials: Cognitive Fog in Veterans
Veterans in GLP-1 alcohol trials sometimes face cognitive fog that hinders participation. This article explores P21, a synthetic peptide, as...
Read articleJul 30, 2026
P21 and Pinealon Synergy for Age-Related Cognitive Decline
P21 and Pinealon, two peptides under FDA review as a nootropic stack, target age-related cognitive decline through neurogenesis and epigenetic
Read articleJul 28, 2026
Selank for Performance Anxiety Under FDA Scrutiny
Selank, a synthetic tuftsin analogue, shows promise for anxiety without sedation, but FDA scrutiny and a lack of performance-specific trials...
Read articleJul 23, 2026
P21 for Chemobrain: Can This Peptide Reverse Chemotherapy-Induced Cognitive Decline?
Chemobrain affects up to 50% of cancer survivors, yet no approved treatment exists. The peptide P21 shows promise in animal...
Read articleJul 20, 2026
P21 vs. Cerebrolysin for Post-Concussion Cognitive Rehabilitation
Comparing P21 and Cerebrolysin for post-concussion cognitive recovery: a walk through the preclinical and clinical evidence, mechanisms, safety, and
Read article